KR100686362B1 - A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity - Google Patents
A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity Download PDFInfo
- Publication number
- KR100686362B1 KR100686362B1 KR1020050097980A KR20050097980A KR100686362B1 KR 100686362 B1 KR100686362 B1 KR 100686362B1 KR 1020050097980 A KR1020050097980 A KR 1020050097980A KR 20050097980 A KR20050097980 A KR 20050097980A KR 100686362 B1 KR100686362 B1 KR 100686362B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- var
- blue
- zizyphus jujuba
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 208000008589 Obesity Diseases 0.000 title claims abstract description 25
- 235000020824 obesity Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title abstract description 30
- 235000008529 Ziziphus vulgaris Nutrition 0.000 title abstract description 7
- 240000003584 Ziziphus jujuba Species 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 241001247821 Ziziphus Species 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000002075 main ingredient Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 42
- 235000012000 cholesterol Nutrition 0.000 abstract description 20
- 239000004615 ingredient Substances 0.000 abstract description 9
- 235000013402 health food Nutrition 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 230000037396 body weight Effects 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 244000126002 Ziziphus vulgaris Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004069 plant analysis Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 식이 유도 비만 모델 쥐에서 청대추 추출물에 의한 체중변화 측정결과를 나타낸 도이며,1 is a diagram showing the weight change measurement results by the extract of blue jujube in diet-induced obesity model rats,
도 2는 식이 유도 비만 모델 쥐에서 청대추 추출물에 의한 혈중 중성지방 의 농도 변화를 측정한 결과를 나타낸 도이다.Figure 2 is a diagram showing the results of measuring the change in the concentration of triglycerides in blood by the extract of blue jujube in diet-induced obesity model rats.
도 3은 식이 유도 비만 모델 쥐에서 청대추 추출물에 의한 혈중 콜레스테롤의 농도 변화를 측정한 결과를 나타낸 도이며Figure 3 is a diagram showing the results of measuring the change in blood cholesterol concentration by the extract of blue jujube in diet-induced obesity model rats
도 4는 식이 유도 비만 모델 쥐에서 청대추 추출물에 의한 후복강 지방의 무게 변화를 측정한 결과를 나타낸 도이다.Figure 4 is a diagram showing the results of measuring the weight change of the posterior cavity fat by the blue jujube extract in diet-induced obesity model rats.
본 발명은 청대추 추출물을 포함하는 비만 예방 및 치료용 조성물에 관한 것이다. The present invention relates to a composition for the prevention and treatment of obesity, comprising blue extract.
최근 우리나라에서는 식습관이 서구화되고, 문화수준이 향상됨에 따라 단순 비만자가 현저히 증가하고 있다. 비만은 고혈압, 동맥경화, 지방간 및 당뇨 등 각종 질병의 발생에 관여하거나 악화시키는 원인이 되고 있다. 따라서 비만은 미리 예방하는 것이 좋으며, 비만증이 된 경우에는 체지방의 감소를 통하여 신체대사가 원활하게 이루어지도록 조절하는 것이 각종 질병의 예방과 건강을 위하여 매우 중요하다. In recent years, as the eating habits have been westernized and the culture level has been improved, simple obesity has increased significantly. Obesity has been a cause of involvement or exacerbation of various diseases such as hypertension, arteriosclerosis, fatty liver and diabetes. Therefore, it is better to prevent obesity in advance, and in case of obesity, it is very important for the prevention and health of various diseases to control body metabolism smoothly by reducing body fat.
지금까지 중국 및 일본 등지에서는 비만 감소를 위하여 오랜 음용 역사가 있는 감비차를 애용하고 있으나, 이는 그 제조방법이 매우 불편하고 손쉽게 음용할 수 있는 형태의 제품이 아니어서 보다 편리하고 간편하게 음용할 수 있는 기능성 음료에 대한 요구가 높아지고 있다.Until now, in China and Japan, Gambia tea, which has a long history of drinking, has been used for reducing obesity, but this is not a product that is very inconvenient and easy to drink. The demand for drinks is increasing.
시중에는 식이섬유 제품, 유단백 등을 이용한 제품, 한약재 성분을 이용한 과립형 제품 등 다양한 형태의 다이어트 제품이 판매되고 있다. 또한 다이어트 음료들도 개발되어 시판되고 있으나, 이들 음료는 유효 성분의 분석과 효능 발현 기작의 과학적 규명이 이루어지지 않고, 적절한 농도 이하로 첨가되는 경우가 대부분이어서 체중 증가 억제 효과면에서 매우 낮은 기호성 음료에 지나지 않은 경우도 있다.There are various types of diet products on the market, such as dietary fiber products, products using milk proteins, and granular products using herbal ingredients. In addition, diet drinks have also been developed and marketed, but these drinks are not scientifically analyzed for the analysis of active ingredients and the mechanism of expression of efficacy. In some cases, it is only.
청대추는 대추가 빨갛게 익기 전의 대추로 갈매기나무과에 속한 대추나무(Zizyphus jujuba Mill.)의 성숙한 과실이다. 유럽 동남부와 아시아 동남부가 원산 지이며 우리나라 마을 부근에서 많이 재배한다. 나무에 가시가 있고 마디 위에 작은 가시가 다발로 난다. 잎은 어긋나고 달걀 모양 또는 긴 달걀 모양이며 3개의 잎맥이 뚜렷이 보인다. 잎의 윗면은 연한 초록색으로 약간 광택이 나며 잎 가장자리에 잔 톱니들이 있다. 잎자루에 가시로 된 턱잎이 있다. 6월에 연한 황록색 꽃이 피며 잎겨드랑이에서 짧은 취산꽃차례를 이룬다. 꽃받침조각·꽃잎·수술은 각각 5개이고 암술은 1개이다. 열매는 핵과로 타원형이고 표면은 적갈색이며 윤이 난다. 외과피는 얇은 혁질이고 점착성이 있으며 갯솜과 같다. 내과피는 딱딱하고 속에 종자가 들어 있으며, 9월에 빨갛게 익는다. 열매인 대추는 날로 먹거나 떡·약식 등의 요리에 이용하며 대추를 9월에 따서 말린 것을 한방에서는 자양·강장·진해·진통·해독 등의 효능이 있어 기력부족·전신통증·불면증·근육경련·약물중독 등에 쓴다. 대추에는 알칼로이드, 단백질, 당류, 유기산, 점액질, 비타민 A·B2·C, 미량의 칼슘, 인, 철 등이 함유되어 있다(본초학, 전국한의과대학 공동교재편찬위원회, 영림사, P558, 2004). Blue jujube is a mature fruit of Zizyphus jujuba Mill. It is native to southeastern Europe and southeastern Asia, and is cultivated in the vicinity of Korean villages. Trees have thorns and bunches of thorns on nodes. The leaves are alternate, egg-shaped or long egg-shaped, with three leaf veins clearly visible. The upper side of the leaf is light green and slightly polished, and there are fine teeth on the edge of the leaf. A petiole has thorn leaves on petioles. Pale yellow-green flowers bloom in June, forming a short inflorescence in the axilla. Calyxes, petals, and stamens are 5 in number and pistil is 1 in number. Fruits are nucleus, oval, reddish brown, glossy. Surgical blood is thin, sticky and sponge-like. The inner skin is hard and has seeds in it and ripens in September. Jujube, which is a fruit, is eaten raw or used for cooking rice cakes, medicines, etc., and dried jujube in September. The herbal medicine has nourishment, tonic, Jinhae, analgesic, and detoxification. Used for drug addiction. Jujube contains alkaloids, proteins, sugars, organic acids, mucus, vitamins A, B2, C, trace amounts of calcium, phosphorus, iron, etc. (Herbal Medicine, Committee for Compiling Teaching Materials, Younglimsa, P558, 2004).
그러나 대추 추출물의 비만 치료 및 예방 효과와 관련된 용도에 관해서는 상기 문헌 어디에도 교시되거나 기재된 바가 없다.However, nothing has been taught or described in the literature regarding the use of jujube extract in relation to the obesity treatment and prophylactic effect.
따라서, 이에 본 발명자들은 본 발명의 청대추 추출물을 고지방, 고콜레스테롤 식이로 유도한 비만 모델 쥐에 섭취시킨 결과, 체중 증가 억제효과, 체내 중성지방 농도 및 콜레스테롤의 농도를 저하시키고, 고밀도콜레스테롤의 농도는 증가시키는 지방대사 촉진효과 및 지방축적 억제효과를 확인함으로써 본 발명을 완성하였다.Therefore, the present inventors ingested the blue jujube extract of the present invention in obese model rats induced by a high fat, high cholesterol diet, the weight gain inhibitory effect, lowering the concentration of triglycerides and cholesterol in the body, the concentration of high density cholesterol Has completed the present invention by confirming the effect of increasing fat metabolism and inhibiting fat accumulation.
본 발명의 목적은 청대추 추출물을 함유하는 비만의 예방 및 치료를 위한 약학조성물 및 건강기능식품을 제공하는 것이다. An object of the present invention is to provide a pharmaceutical composition and health functional food for the prevention and treatment of obesity containing blue jujube extract.
상기 목적을 달성하기 위해 본 발명은 청대추 추출물을 함유하는 비만의 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the prevention and treatment of obesity containing the blue jujube extract.
상기 추출물은 물, 에탄올, 메탄올과 같은 저급 알콜 또는 이들의 혼합용매 바람직하게는 물 또는 에탄올 가용추출물, 보다 바람직하게는 10 내지 95%의 에탄올에 가용된 추출물을 포함한다.The extract includes water, ethanol, lower alcohols such as methanol or mixed solvents thereof, preferably water or ethanol soluble extract, more preferably 10 to 95% of the soluble extract in ethanol.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 청대추 추출물은 하기와 같이 수득될 수 있다.Blue jujube extract of the present invention can be obtained as follows.
본 발명의 청대추 추출물은 청대추를 세절하여 건조한 후, 추출 용매로 물과 에탄올의 혼합용매를 1 내지 50배, 바람직하게는 10내지 30배 부피량을 10 내지 50℃, 바람직하게는 실온에서 1시간 내지 5일간, 바람직하게는 1 내지 4일 동안 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법으로, 바람직하게는 냉침추출법으로 추출하거나, 또는 추출 용매로 증류수를 1 내지 40배, 바람직하게는 5 내지 20배 부피량을 30 내지 150℃, 바람직하게는 60 내지 120℃의 추출 온도에서 0.5 내지 10시간, 바람직하게는 1 내지 5시간 침적, 냉침추출, 열수추출, 초 음파 추출, 환류냉각 추출 등의 추출방법으로, 바람직하게는 환류냉각 추출한 후 추출액을 원심분리 및 여과, 농축하여 본 발명의 추출물을 수득한다.The blue jujube extract of the present invention is chopped and dried blue jujube, and then a mixed solvent of water and ethanol 1 to 50 times, preferably 10 to 30 times the volume of 10 to 50 ℃, preferably at room temperature as an extraction solvent 1 hour to 5 days, preferably 1 to 4 days extraction method such as cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, preferably by cold extraction, or distilled water with an extraction solvent 1 to 40 Pear, preferably 5 to 20 times the volume amount of 0.5 to 10 hours, preferably 1 to 5 hours at an extraction temperature of 30 to 150 ℃, preferably 60 to 120 ℃, cold extraction, hot water extraction, ultrasonic Extraction method such as extraction, reflux cooling extraction, and the like, preferably after reflux cooling extraction, the extract is centrifuged, filtered and concentrated to obtain the extract of the present invention.
또한, 추가로 통상의 분획 공정을 수행할 수도 있다(Harborne J.B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed., pp6-7, 1998). In addition, conventional fractionation processes can also be carried out (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. , Pp 6-7, 1998).
상기와 같은 방법으로 얻어진 청대추 추출물은 고지방, 고콜레스테롤 식이로 유도한 비만 모델 쥐에 섭취시킨 결과, 체중 증가 억제효과, 체내 중성지방 농도 및 콜레스테롤의 농도를 저하시키고, 고밀도콜레스테롤의 농도는 증가시키는 지방대사 촉진효과 및 지방축적 억제효과가 탁월함을 확인하였다.The blue jujube extract obtained by the above method was ingested in a high-fat, high-cholesterol-induced obesity model rat, resulting in weight loss inhibitory effect, lowering the concentration of triglycerides and cholesterol in the body, and increasing the concentration of high density cholesterol. It was confirmed that the effect of promoting fat metabolism and inhibiting fat accumulation was excellent.
본 발명은 상기 제조방법으로 수득된 청대추 추출물을 유효성분으로 함유하는 비만의 예방 및 치료를 위한 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of obesity containing the blue jujube extract obtained by the production method as an active ingredient.
본 발명의 비만의 예방 및 치료용 약학조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50 중량%로 포함한다.The pharmaceutical composition for preventing and treating obesity of the present invention comprises 0.1 to 50% by weight of the extract based on the total weight of the composition.
본 발명의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물 또는 화합물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract or compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100mg/kg으로, 바람직하게는 20 내지 40mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위을 한정하는 것은 아니다.Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 20 to 40 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다.The extract of the present invention can be administered to mammals such as mice, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명은 비만의 예방 및 치료의 효과를 나타내는 상기 청대추 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공한다. 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류, 분말, 과립, 정제, 캡슐 또는 음료 등이 있다.The present invention provides a dietary supplement comprising the above-mentioned blue jujube extract and a foodstuff acceptable food supplement additive exhibiting the effect of preventing and treating obesity. Examples of the food to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules or beverages.
또한, 비만의 예방 및 치료 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. It may also be added to food or beverages for the purpose of preventing and treating obesity. At this time, the amount of the extract in the food or beverage can be added in 0.01 to 15% by weight of the total food weight, the health beverage composition is added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml Can be.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 청대추 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except the above-mentioned blue jujube extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 청대추 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the blue jujube extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
실시예 1. 청대추 추출물의 제조Example 1 Preparation of Blue Jujube Extract
1-1. 청대추 물 추출물의 제조1-1. Preparation of Blue Jujube Water Extract
농장에 직접 채취한 청대추 500g을 깨끗한 물로 수세한 후 2차 증류수 6L를 가하고 약 3시간 동안 전기약탕기로 추출하여 여과하고 감압회전농축기로 농축한 다음, 동결건조기(Freeze dryer)에서 동결건조하여 청대추 물 추출물 25g을 수득하였다(수득률 5%).500 g of blue jujube harvested directly on the farm was washed with clean water, and then 6L of secondary distilled water was added, extracted with an electric bath for 3 hours, filtered, concentrated in a vacuum rotary concentrator, and freeze-dried in a freeze dryer. 25 g of jujube water extract was obtained (yield 5%).
1-2. 청대추 에탄올 추출물의 제조1-2. Preparation of Blue Jujube Ethanol Extract
농장에서 직접 채취한 청대추 500g을 깨끗한 물로 수세한 후 자연 건조하여 분말화한 후, 70% 에탄올 10℃를 가하고 상온에서 약 72 시간씩 2회 반복하여 추출한 다음, 여과하고 감압건조하여 청대추 주정 추출물 20g을 수득하였다(수득률 4%).500g of directly harvested blue jujube was washed with clean water, dried naturally and powdered. After adding 10% of 70% ethanol and extracting it twice at room temperature for about 72 hours, it was filtered and dried under reduced pressure. 20 g of extract were obtained (yield 4%).
참고예 1. 실험동물 Reference Example 1. Experimental Animal
실험대상 동물은 수컷 마우스(C57BL/6J, 5주령)를 구입(효창싸이언스)하여 사용하였고, 30% 지방과 1% 콜레스테롤을 함유한 먹이를 17주 동안 먹이는 고지방 고콜레스테롤 식이(High-fat & high-cholesterol diet)요법으로 비만을 유도하였다. 고사육 환경은 항온 25± 2℃, 항습 50± 5%, 12시간 간격의 명암주기(dark-light cycle)로 일정한 조건을 유지하였다.Animals were purchased from male mice (C57BL / 6J, 5 weeks old) (Hyochang Science), and were fed high fat and high cholesterol diets containing 30% fat and 1% cholesterol for 17 weeks (High-fat & high). -cholesterol diet therapy induced obesity. High breeding environment was maintained at a constant temperature of 25 ± 2 ℃,
실험예 1. 체중 증가 측정Experimental Example 1. Measurement of weight gain
본 발명의 청대추 추출물이 동물 모델의 체중변화에 어떤 영향을 미치는지 알아보기 위하여 하기와 같은 실험을 수행하였다.The following experiment was performed to determine the effect of the blue jujube extract of the present invention on the weight change of the animal model.
상기 참고예 1의 방법으로 유도한 비만 쥐에 사료에 청대추 추출물을 4주 동안 0.5% 로 첨가하여 매일 경구 투여하였다. 비만 쥐의 체중 변화를 확인하기 위해, 청대추 추출물을 투여한 후 각 주 별로 체중을 측정하였다. 랫트의 체중을 측정하기 위하여, 저울에 랫트를 담을 수 있는 상자를 두고 영점을 조절한 후 랫트의 행동이 멈추었을 때의 수치를 측정하였다.The obese rats induced by the method of Reference Example 1 were added orally with 0.5% of blue jujube extract to the feed for 4 weeks and orally administered daily. In order to confirm the weight change of obese rats, body weights were measured each week after the administration of the blue jujube extract. In order to measure the weight of the rat, a box containing the rat was placed on the scale and the zero point was adjusted, and then the value when the rat's behavior stopped.
실험 수행 결과, 하기 도 1에서 보는 바와 같이, 4주 동안의 청대추 추출물을 사료에 0.5% 첨가하여 투여 한 경우 투여하지 않은 대조군에 비하여 4주까지 15% 의 탁월한 체중증가 억제효과를 확인할 수 있었다.As a result of the experiment, as shown in Figure 1, it was confirmed that when the addition of 0.5% of blue jujube extract to the feed for 4 weeks, compared to the control group did not administer 15% excellent weight gain inhibitory effect up to 4 weeks .
실험예 2. 혈중 지질 변화 측정Experimental Example 2 Measurement of Changes in Lipids in Blood
본 발명의 청대추 추출물을 이용하여 동물 모델에서 혈중 지방 및 콜레스테롤 농도 감소 효과가 있는지를 확인하기 위하여 기존 문헌에 기재된 실험 방법을 응용하여 하기와 같은 과정으로 실험을 수행하였다(Van Heek et al., J. Clin. Invest., 99, 385-390, 1997).In order to determine whether there is an effect of reducing blood fat and cholesterol concentration in animal models using the extract of blue jujube of the present invention, the experiment was performed by the following procedure by applying the experimental method described in the existing literature (Van Heek et al., J. Clin. Invest. , 99 , 385-390, 1997).
상기 참고예 1의 방법으로 유도한 비만 쥐에게 사료에 청대추 추출물을 4주 동안 0.5% 로 첨가하여 매일 경구 투여하여 실험군과 대조군으로 나누었다. 청대추 추출물을 경구투여하기 시작한 후 5주 경과한 쥐를 희생 전 12시간 동안 절식시켜 공복상태로 만들었다. 그리고 50㎎/㎏의 소듐 펜토바르비탈 (Sodium pentobarbital)을 복강 주사하여 마취시킨 다음 복부 하대정맥(inferior venacava)으로부터 공복 혈액을 채취하였다. 채취된 혈액은 항응고제를 처리한 후 3,000 rpm, 4 ~ 15분간 원심 분리하여 혈장을 분리하였다. The obese rats induced by the method of Reference Example 1 were added orally to the feed by 0.5% for 4 weeks, and divided into the experimental group and the control group by daily oral administration. Mice five weeks after oral administration of the blue jujube extract were fasted for 12 hours before sacrifice, and then fasted. Then, anesthesia was injected by intraperitoneal injection of 50 mg / kg sodium pentobarbital, and fasting blood was collected from the inferior venacava. The collected blood was centrifuged for 4-15 minutes at 3,000 rpm after treatment with anticoagulant to separate plasma.
혈장 10 ㎕에 1.5 ㎖의 중성지질 측정 키트액 및 1.5 ㎖의 콜레스테롤 측정 키트액을 1:1로 섞은 후 37℃ 에서 5분간 반응시키고, 마이크로 플레이트 분석기 (microplate reader)에서 총콜레스테롤은 492 nm, 중성지방은 540 nm에서 각각 흡광도를 측정하여 혈중 농도[mg/dl]를 정량하였다. 중성지방 및 콜레스테롤의 정량 환산은 이들의 표준 용액에 대하여 농도별로 흡광도를 측정하여 얻어진 값으로 표준 농도곡선을 그리고 이를 이용하여 정량하였다. 1.5 ml of neutral lipid measurement kit solution and 1.5 ml of cholesterol measurement kit solution were mixed 1: 1 in plasma and reacted at 37 ° C. for 5 minutes, and total cholesterol was 492 nm and neutral in a microplate reader. Fats were quantified in blood concentration [mg / dl] by measuring absorbance at 540 nm, respectively. Quantitative conversion of triglycerides and cholesterol was determined by using a standard concentration curve with the values obtained by measuring absorbance for each standard solution by concentration.
실험 결과 하기 도 2 및 도 3에서 보이는 바와 같이, 실험군인 청대추 추출물을 섭취한 쥐의 혈중 중성지방 및 콜레스테롤의 농도가 저하됨이 확인되었으며 혈중 HDL이 증가되는 것 확인하였다. 이는 콜레스테롤을 간으로 이동시키는 역할을 하는 HDL이 혈중에 증가하여 콜레스테롤의 대사가 활발하게 벌어지는 것을 의미하는 것으로 비만 쥐에서 청대추 추출물이 콜레스테롤의 대사를 원활하게 하는 것을 확인할 수 있었다. Experimental results As shown in Figures 2 and 3, it was confirmed that the concentration of triglycerides and cholesterol in the blood of the rats ingested the extract of blue jujube in the experimental group and the HDL in the blood was increased. This means that HDL, which plays a role in moving cholesterol to the liver, increases in blood and metabolizes cholesterol actively, and it was confirmed that blue jujube extract smoothed the metabolism of cholesterol in obese mice.
실험예 3. 체내 지방축적 영향 측정Experimental Example 3. Measurement of fat accumulation effect in the body
본 발명의 청대추 추출물이 지방의 체내 축적에 미치는 영향을 알아보기 위 하여 하기와 같은 실험을 수행하였다. In order to determine the effect of the blue jujube extract of the present invention on the accumulation of fat in the body, the following experiment was performed.
청대추 추출물을 경구투여하기 시작한 후 5주 경과한 쥐를, 희생 전 12시간 동안 절식시켜 공복상태로 만들었고, 50㎎/㎏의 소듐 펜토바르비탈(Sodium pentobarbital)을 복강 주사하여 마취시킨 다음 실험동물을 해부하여 후 복강에서 지방을 적출하여 무게를 측정하였다. Rats 5 weeks after oral administration of the blue jujube extract were fasted for 12 hours before sacrifice, and fasted, and anesthetized by intraperitoneal injection of 50 mg / kg sodium pentobarbital. After dissection, the fat was extracted from the abdominal cavity and weighed.
실험결과 도 4에서 보는 바와 같이, 비만 쥐에 4주 동안 청대추 추출물 투여군한 실험군이 대조군에 비하여 9% 의 지방축적 억제 효과를 보임을 확인 할 수 있었다. Experimental results As shown in Figure 4, it was confirmed that the experimental group administered with the blue jujube extract for 4 weeks in obese rats showed a 9% fat accumulation inhibitory effect compared to the control group.
실험예 4. 급성독성시험Experimental Example 4. Acute Toxicity Test
실시예 1의 청대추 추출물 2g/kg을 마우스 10마리에게 경구 투여하여 변화를 관찰하였는데 사망예를 전혀 관찰할 수 없었으며 체중 증가, 사료 섭취량 등에서 전혀 유의한 이상을 발견할 수 없었다. 따라서 본 발명의 청대추 추출물은 안전한 약물임을 확인할 수 있었다.Changes were observed by oral administration of 2 g / kg of the blue jujube extract of Example 1 to 10 mice, but no death was observed, and no significant abnormalities were found in weight gain and feed intake. Therefore, the extract of blue jujube of the present invention was confirmed to be a safe drug.
하기에 상기 조성물의 제제예를 예시하나 이는 본 발명을 이에 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Examples of the formulation of the composition are given below, but the present invention is not intended to be limited thereto but merely to explain in detail.
하기에 본 발명의 추출물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a preparation example of a composition containing an extract of the present invention will be described, but the present invention is not intended to be limited thereto but only to be described in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
청대추 추출물 20 mg
유당 100 mgLactose 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
청대추 추출물 10 mg
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조 Formulation Example 3 Preparation of Capsule
청대추 추출물 10 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
청대추 추출물 10 mg
만니톨 180 mg
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
청대추 추출물 20 mg
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한 다.After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.
제제예 6. 건강 식품의 제조Formulation Example 6 Preparation of Healthy Food
청대추 추출물 1000 ㎎Blue Date Extract 1000 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎Calcium Carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예 7. 건강 음료의 제조Formulation Example 7 Preparation of Healthy Drink
청대추 추출물 1000 ㎎Blue Date Extract 1000 mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g oligosaccharides
매실농축액 2 gPlum concentrate 2 g
타우린 1 g1 g of taurine
정제수를 가하여 전체 900 ㎖Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a relatively suitable component for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
본 발명의 청대추 추출물은 고지방, 고콜레스테롤 식이로 유도한 비만 모델 쥐에서 체중 증가 억제효과, 체내 중성지방 농도 및 콜레스테롤의 농도를 저하시키고, 고밀도콜레스테롤의 농도는 증가시키는 지방대사 촉진효과 및 지방축적 억제효과fmf 가져 비만의 예방 및 치료용 약학조성물 및 건강기능식품으로 유용하게 이용될 수 있다. Cheongjuju extract of the present invention is a high fat, high cholesterol diet-induced fat metabolism-promoting effect and fat accumulation in obese model rats to lower the weight gain inhibitory effect, decrease the concentration of triglyceride and cholesterol in the body, increase the concentration of high density cholesterol Inhibitory effect fmf can be useful as a pharmaceutical composition and health functional food for the prevention and treatment of obesity.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050097980A KR100686362B1 (en) | 2005-10-18 | 2005-10-18 | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050097980A KR100686362B1 (en) | 2005-10-18 | 2005-10-18 | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100686362B1 true KR100686362B1 (en) | 2007-02-22 |
Family
ID=38104479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050097980A KR100686362B1 (en) | 2005-10-18 | 2005-10-18 | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100686362B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160011846A (en) * | 2014-07-23 | 2016-02-02 | 상지대학교산학협력단 | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020089251A (en) * | 2002-10-25 | 2002-11-29 | 정일광 | A composition applicable to a skin for diet and an application thereof |
KR20040066606A (en) * | 2003-01-20 | 2004-07-27 | 야스요 마에자와 | A composition applicable to a skin for diet and an application thereof |
-
2005
- 2005-10-18 KR KR1020050097980A patent/KR100686362B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020089251A (en) * | 2002-10-25 | 2002-11-29 | 정일광 | A composition applicable to a skin for diet and an application thereof |
KR20040066606A (en) * | 2003-01-20 | 2004-07-27 | 야스요 마에자와 | A composition applicable to a skin for diet and an application thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160011846A (en) * | 2014-07-23 | 2016-02-02 | 상지대학교산학협력단 | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof |
KR101690369B1 (en) * | 2014-07-23 | 2016-12-27 | 상지대학교산학협력단 | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100813222B1 (en) | Medicinal herbal extract having anti-obesity effect | |
KR102511361B1 (en) | Composition for Preventing, Improving or Treating Postmenopausal Syndrome Comprising Rosa rugosa Thunberg Extract | |
KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
KR100863524B1 (en) | Composition for preventing and treating metabolic diseases comprising the extract of lysimachiae foenum-graeci herba | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR101075554B1 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
KR100686362B1 (en) | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity | |
KR100555904B1 (en) | A herbal mixture extract of Pleurotus eryngii and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis | |
KR100706284B1 (en) | Pharmaceutical composition comprising the seed extract of Alpinia oxyphylla miquel for treating or preventing obesity and improving lipid metabolism | |
KR100875247B1 (en) | Composition for preventing and treating metabolic diseases comprising the extract of lysimachiae foenum-graeci herba | |
KR100881369B1 (en) | A composition comprising isoliquiritigenin isolated from glycyrrhiza radix for treating and preventing drug intoxication or withdrawal | |
KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR20080079374A (en) | Composition comprising extract of crude drug mixture and the preparation method therof | |
KR100899377B1 (en) | A composition comprising an extract of Erigeron canadensis L. for preventing and treating lipid metabolism disorder | |
KR102321579B1 (en) | Composition for preventing, ameliorating or treating osteoporosis containing processed KIOM Polygoni multiflori radix extract as effective component | |
KR101368383B1 (en) | Composition for prevention and treatment of obesity or metabolic diseases comprising deoxyshikonin | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
KR100706283B1 (en) | Pharmaceutical composition comprising the extract of Amomum xanthiodes Wallich for treating or preventing obesity and improving lipid metabolism | |
KR100909572B1 (en) | The composition for the treatment of diabetes and metabolic syndrome containing obovatol and its synthesized derivatives | |
KR20170130082A (en) | A Composition Comprising the root extract of Achyranthes japonica NAKAI for preventing or improving the hormonal abnormal syndrome in women | |
KR20220164353A (en) | A composition Comprising the combined herbal extract consisting of Curcuma longa Linne and Citrus junos Tanaka for hepato-protective activity and for preventing or treating non-alcoholic fatty liver disease | |
WO2015088167A1 (en) | Bean leaves or bean stems having high isoflavone derivative content, and method for preparing same | |
KR101651105B1 (en) | ISOLATED SINGLE COMPOUND FROM Mori Cortex Radicis ITS APPLICATION IN TREATING AND PREVENTING OBESITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130121 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140116 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150213 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161223 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180125 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181224 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 14 |